Authors: M Horstmann A S Merseburger E von der Heyde J Serth G Wegener M Mengel G Feil J Hennenlotter U Nagele A Anastasiadis C Bokemeyer A Stenzl M Kuczyk
Publish Date: 2005/08/04
Volume: 131, Issue: 11, Pages: 715-722
Abstract
The prognostic value of bFGF for surgically treated renal cell cancer RCC patients was evaluated by immunohistochemistry IHC and the tissue microarray technique TMA Additionally preoperative serum bFGF levels were correlated to tumour stage and the presence of metastases at initial diagnosis Serum levels of bFGF were measured by ELISA in 39 healthy volunteers in 37 patients with benign urologic diseases and in 74 RCC patients 26 of whom revealed lymph node or distant metastases bFGF expression as detected by IHC was investigated in 777 tissue cores from 259 different RCC patients median followup 138 36–240 months Eighty eight patients died from tumour progression For each patient the TMA slides contained a tissue core from the primary tumour its invasion front and the normal renal parenchyma bFGF serum levels were higher in RCC patients vs healthy volunteers P001 and vs patients with benign urologic diseases P001 Metastasized patients revealed higher bFGF serum levels than organconfined specimens P001 As detected by IHC only increased bFGF expression in the invasion front tissue correlated with the patients’ longterm survival log rank test P=003 In multivariate analysis regional LN metastases P001 the histological grading P001 and an increased bFGF expression in the invasion front P=004 independently predicted the patients’ clinical prognosis Not the expression of bFGF in the primary tumour but in its invasion front reflects the aggressiveness of RCC hereby indicating a different biological potential within both areas The value of bFGF serum levels as indicators of systemic tumour dissemination remains to be determined
Keywords: